5 mg/dL for placebo/simvastatin (hereafter placebo) vs 53
Introduction It is well known fact that deposition of LDL-C and cholesterol-rich Apo-B containing lipoproteins in the arterial walls is responsible for atherosclerosis
The ENHANCE trial was conducted in patients with Background
Ezetimibe has been shown to significantly reduce levels of LDL-C and recently, as demonstrated in the IMPROVE-IT trial, to reduce the rate of cardiovascular events in high-risk patients
4% in the different meta‐analyses Vytorin (ezetimibe/simvastatin) is a brand-name drug prescribed for certain types of high cholesterol in adults and some children
1 Recommended Dosing
In clinical trials, the most commonly reported side effects, regardless of cause, included headache (5
8 percent)
Ezetimibe is a selective cholesterol absorption inhibitor, whether it has a positive effect on CVD events Ezetimibe lowers low-density lipoprotein cholesterol (LDL-C) by 15-20% when used alone 2 as compared to 5-10% from doubling the dose of statin
Cannon, MD, FACC, professor of medicine at Harvard Medical School and physician at Brigham and Women's Hospital, and enrolled 18,144 The landmark trial for ezetimibe is called the Improved Reductions of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
This trial demonstrated that statin/ezetimibe combinations with a high-intensity statin overall had better efficacy on the lipid Ezetimibe and simvastatin tablets dosage should not exceed 10 mg/20 mg/day (or 10 mg/40 mg/day for patients who have previously taken simvastatin 80 mg/day chronically, e
Ezetimibe is a lipid lowering medication that is able to inhibit dietary cholesterol
053 Trial included patients aged ≥18 years with fasting LDL-C ≥100 mg/dL if they had ASCVD and/or HeFH, or ≥130 mg/dL if they had multiple CV risk factors
Allocation to simvastatin plus ezetimibe yielded an average LDL cholesterol difference of 0·85 mmol/L (SE 0·02; with about two-thirds compliance) during a median follow-up of 4·9 years and produced a 17% proportional reduction in major atherosclerotic events (526 [11·3%] simvastatin plus Results
Statins reduce the amount of cholesterol and lipoproteins that our bodies produce, by inhibiting an enzyme The ESSENTIAL (Effects of Statin Monotherapy and Statin/Ezetimibe Combination Therapy on Non-alcoholic Steatohepatitis in patients with Hyperlipidemia and Fatty Liver) study was an investigator-initiated, randomized, open-label, prospective, active-controlled clinical trial to examine the efficacy of ezetimibe 10 mg/day orally combined with Several epidemiological trials have raised concerns of an increased risk of cancer associated with low total serum cholesterol levels that have been reproduced in a small number of randomized controlled statin trials
Study Design
Objective: To determine the effect on outcomes and risks of combination ezetimibe and simvastatin compared with simvastatin monotherapy to The IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) showed that the combination of ezetimibe and simvastatin improved cardiovascular outcomes compared with simvastatin monotherapy
Aims: The aim of this study was to evaluate the low-density lipoprotein cholesterol lowering efficacy and safety of a bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination in patients with hypercholesterolemia and a high risk of cardiovascular disease receiving maximally tolerated statin therapy
Compared with either placebo or simvastatin alone, allocation to ezetimibe plus simvastatin was not associated with any excess of myopathy, hepatic toxicity, or biliary complications during the first year of follow-up
g
The addition of ezetimibe to statin therapy should be considered for The controversy about whether ezetimibe combined simvastatin can cause cancer comes from a 4-year clinical trial, Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study NCT00092677), with a total of 1873 patients (Rossebø et al
Compared with placebo, LDL-C was reduced by 61% (2
1 Clinical Trials Experience
4 mmol per liter) in the simvastatin–ezetimibe group, as compared with 69
Abstract Background: Evidence regarding the primary prevention of coronary artery disease events by low-density
The median time-averaged LDL-C values from 4 weeks until the end of the trial were 69
Objective To compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking
In randomized trials (SHARP [Study of Heart and Renal Protection], IMPROVE ‐IT [Improved Reduction of Outcomes: Vytorin Efficacy
a statin in clinical trials, 3587 (32%) were 65 years of age and older, and 924 (8%) were 75 years of age and older In a multiple-dose trial with ezetimibe given 10 mg once daily
The IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) showed that the combination of ezetimibe and simvastatin improved cardiovascular outcomes compared with
, for 12 months or more, without evidence of muscle toxicity) while taking lomitapide
The definitive IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study will reveal the impact of ezetimibe in decreasing coronary vascular disease
053 Trial included patients aged ≥18 years with fasting LDL-C ≥100 mg/dL if they had ASCVD and/or HeFH, or ≥130 mg/dL if they had multiple CV risk factors
This is not a complete list of side effects and others may occur
Allocation to simvastatin plus ezetimibe yielded an average LDL cholesterol difference of 0·85 mmol/L (SE 0·02; with about two-thirds compliance) during a median follow-up of 4·9 years and produced a 17% proportional reduction in major
5% to 98
No additional prescription lipid-modifying drugs were allowed during the trial
They lower cholesterol in different ways: Ezetimibe blocks cholesterol being absorbed from the small intestine
As a result, guideline recommendations differ for this age group compared with younger patients
22 The subanalysis showed that patients aged ≥75 years had a 20% relative reduction in the primary